Healthcare Spotlight

The healthcare industry is having a moment lately, as massive technological breakthroughs continue to lead to blockbuster new therapies. If you’ve been wanting to invest in healthcare, three companies in particular are poised to potentially dominate the market by 2030. Here’s a deeper look.

Vertex (NASDAQ: VRTX)

With a market cap of more than $120 billion, Vertex Pharmaceuticals is already one of the biggest drug companies on the planet. But there is still a lot of room to grow. So far, the company has focused primarily on treatments for cystic fibrosis, but they are starting to branch out. From Casgevy for sickle cell disease to a variety of therapeutics for Type 1 diabetes, kidney disease, and more that are currently in clinical trials, Vertex is massively increasing its reach.

Viking (NASDAQ: VKTX)

Viking Therapeutics already has a market cap of $5.2 billion, despite not yet having a single product on the market. This is largely due to the incredible clinical trial success of its weight loss drug, VK2735. But Viking isn’t a one-trick pony. The company is also showing tremendous clinical trial results for its nonalcoholic steatohepatitis (NASH) drug, VK2809. In addition, Viking has a treatment for a rare genetic disorder currently in phase 1b studies.

TransMedics (NASDAQ: TMDX)

Are medical devices more your style? TransMedics Group has developed a revolutionary new technology to keep organs functioning on their way to transplant recipients. Known as the Organ Care System, or OCS, this breakthrough makes it far more likely for donated organs to reach their intended recipients. It also reduces the chances of post-transplant complications.

So far, the biggest hurdle has been finding enough airplanes to transport the organs. But TransMedics recently solved that problem by acquiring a charter plane operator and building its own aircraft fleet. The OCS may well become the standard of care in the U.S., and will likely eventually expand globally. This puts TransMedics in a great position for rapid growth.

Neither Lisa Fritscher nor Stocks.News have positions in these companies.